Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220874541> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4220874541 endingPage "423" @default.
- W4220874541 startingPage "418" @default.
- W4220874541 abstract "Background HER2-positive breast cancer is an aggressive tumor subtype and it is usually associated with worse clinical outcomes. Given the advances in HER2-targeted therapies, we hypothesized that HER2 amplification is no longer a marker of poor prognosis. Methods We conducted a population-based observational study employing two independent cohorts of patients with breast cancer. Samples from the METABRIC cohort were collected before clinical availability of HER2-targeted therapies, whereas samples from the SCAN-B cohort were collected afterward. The primary endpoint was overall survival (OS). Results A total of 5121 patients were included in the analyses. In both cohorts, HER2-positive tumors were more likely to be node-positive (P < .05) and high grade (P < .001). Before HER2-targeted agents, HER2 patients had a significantly worse 5-year OS than hormone receptor-positive (HR+) patients (63.4% vs. 83.0%, HR = 2.49, P < .001). In contrast, after HER2-targeted agents entered clinical practice, 5-year OS no longer differed (88.3% vs. 90.4%, HR = 1.24, P = .17). Additionally, in an exploratory analysis using PAM50 subtypes, we identified that, after HER2-targeted therapies were implemented, patients clinically HER2-negative but PAM50-HER2-enriched have a lower OS (HR = 1.99, P = .009) than those who are both HER2-positive and PAM50-HER2-enriched, since they have not benefitted from HER2-targeted therapies. Conclusions HER2-targeted therapies dramatically altered the natural history of HER2-positive breast cancer, with overall survival approaching those of luminal subtype. HER2 positivity is no longer a marker of poor prognosis if access to HER2-targeted therapies is granted. Future trials should assess whether HER2-negative PAM50-HER2-enriched patients may also benefit from such therapies." @default.
- W4220874541 created "2022-04-03" @default.
- W4220874541 creator A5003076812 @default.
- W4220874541 creator A5028036586 @default.
- W4220874541 creator A5049795402 @default.
- W4220874541 creator A5071617604 @default.
- W4220874541 date "2022-07-01" @default.
- W4220874541 modified "2023-10-16" @default.
- W4220874541 title "Overall Survival for HER2-Positive Breast Cancer Patients in the HER2-Targeted Era: Evidence From a Population-Based Study" @default.
- W4220874541 cites W1546709038 @default.
- W4220874541 cites W2005895632 @default.
- W4220874541 cites W2040958097 @default.
- W4220874541 cites W2097255042 @default.
- W4220874541 cites W2114843025 @default.
- W4220874541 cites W2115528316 @default.
- W4220874541 cites W2131994307 @default.
- W4220874541 cites W2132619562 @default.
- W4220874541 cites W2141393790 @default.
- W4220874541 cites W2149441684 @default.
- W4220874541 cites W2157840751 @default.
- W4220874541 cites W2162982444 @default.
- W4220874541 cites W2479807964 @default.
- W4220874541 cites W2560406314 @default.
- W4220874541 cites W2792135005 @default.
- W4220874541 cites W3003870469 @default.
- W4220874541 cites W3049370161 @default.
- W4220874541 doi "https://doi.org/10.1016/j.clbc.2022.03.004" @default.
- W4220874541 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35430163" @default.
- W4220874541 hasPublicationYear "2022" @default.
- W4220874541 type Work @default.
- W4220874541 citedByCount "3" @default.
- W4220874541 countsByYear W42208745412022 @default.
- W4220874541 countsByYear W42208745412023 @default.
- W4220874541 crossrefType "journal-article" @default.
- W4220874541 hasAuthorship W4220874541A5003076812 @default.
- W4220874541 hasAuthorship W4220874541A5028036586 @default.
- W4220874541 hasAuthorship W4220874541A5049795402 @default.
- W4220874541 hasAuthorship W4220874541A5071617604 @default.
- W4220874541 hasConcept C121608353 @default.
- W4220874541 hasConcept C126322002 @default.
- W4220874541 hasConcept C143998085 @default.
- W4220874541 hasConcept C201903717 @default.
- W4220874541 hasConcept C2777329042 @default.
- W4220874541 hasConcept C2779786085 @default.
- W4220874541 hasConcept C2781164504 @default.
- W4220874541 hasConcept C2781230642 @default.
- W4220874541 hasConcept C2908647359 @default.
- W4220874541 hasConcept C530470458 @default.
- W4220874541 hasConcept C71924100 @default.
- W4220874541 hasConcept C72563966 @default.
- W4220874541 hasConcept C99454951 @default.
- W4220874541 hasConceptScore W4220874541C121608353 @default.
- W4220874541 hasConceptScore W4220874541C126322002 @default.
- W4220874541 hasConceptScore W4220874541C143998085 @default.
- W4220874541 hasConceptScore W4220874541C201903717 @default.
- W4220874541 hasConceptScore W4220874541C2777329042 @default.
- W4220874541 hasConceptScore W4220874541C2779786085 @default.
- W4220874541 hasConceptScore W4220874541C2781164504 @default.
- W4220874541 hasConceptScore W4220874541C2781230642 @default.
- W4220874541 hasConceptScore W4220874541C2908647359 @default.
- W4220874541 hasConceptScore W4220874541C530470458 @default.
- W4220874541 hasConceptScore W4220874541C71924100 @default.
- W4220874541 hasConceptScore W4220874541C72563966 @default.
- W4220874541 hasConceptScore W4220874541C99454951 @default.
- W4220874541 hasFunder F4320321091 @default.
- W4220874541 hasFunder F4320322025 @default.
- W4220874541 hasFunder F4320322502 @default.
- W4220874541 hasIssue "5" @default.
- W4220874541 hasLocation W42208745411 @default.
- W4220874541 hasLocation W42208745412 @default.
- W4220874541 hasOpenAccess W4220874541 @default.
- W4220874541 hasPrimaryLocation W42208745411 @default.
- W4220874541 hasRelatedWork W100456685 @default.
- W4220874541 hasRelatedWork W2010059199 @default.
- W4220874541 hasRelatedWork W2087909560 @default.
- W4220874541 hasRelatedWork W2138094362 @default.
- W4220874541 hasRelatedWork W2138977450 @default.
- W4220874541 hasRelatedWork W2170658448 @default.
- W4220874541 hasRelatedWork W2360887166 @default.
- W4220874541 hasRelatedWork W2481553405 @default.
- W4220874541 hasRelatedWork W4242374293 @default.
- W4220874541 hasRelatedWork W4376138599 @default.
- W4220874541 hasVolume "22" @default.
- W4220874541 isParatext "false" @default.
- W4220874541 isRetracted "false" @default.
- W4220874541 workType "article" @default.